View ValuationINNOVATE 将来の成長Future 基準チェック /06現在、 INNOVATEの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Construction 収益成長11.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2025 Results on Aug 05, 2025INNOVATE Corp. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 12, 2025INNOVATE Corp., Annual General Meeting, Jun 12, 2025.お知らせ • Apr 17INNOVATE Corp. to Report Q1, 2025 Results on May 06, 2025INNOVATE Corp. announced that they will report Q1, 2025 results After-Market on May 06, 2025お知らせ • Feb 28INNOVATE Corp. to Report Q4, 2024 Results on Mar 31, 2025INNOVATE Corp. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025お知らせ • Jan 22INNOVATE Corp. Announces U.S. Food and Drug Administration Approved the MediBeacon TGFR for the Assessment of Kidney Function in Patients with Normal or Impaired Renal FunctionINNOVATE Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The approval of the TGFR by the FDA demonstrates proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis. The potential applications for the TGFR are numerous, and look forward to exploring them with clinicians both in the hospital and outpatient settings. The timing of FDA approval aligns well with the Fourth Quarter 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al in Kidney International with data that supports the utility of MediBeacon's patented agent Lumitrace. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within + - 30% of measured GFR (mGFR) values. For more information, including the FDA Summary of Safety and Effectiveness Data, refer to.お知らせ • Oct 17INNOVATE Corp. to Report Q3, 2024 Results on Nov 06, 2024INNOVATE Corp. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024お知らせ • Sep 04INNOVATE Regains Compliance with NYSE Minimum Price RequirementINNOVATE Corp. (the ‘Company’) announced that it has received a letter from the New York Stock Exchange (‘NYSE’) dated August 27, 2024 (the ‘Compliance Notice’), notifying the Company that it is no longer considered below the NYSE’s continued listing criterion of a minimum average share price of USD 1.00 over a 30 trading-day period (the ‘NYSE Minimum Price Requirement’). ‘The Company’s team shared that we have received notification from the New York Stock Exchange regaining listing compliance,’ said Paul Voigt, the Company’s Chief Executive Officer. ‘Regaining compliance with NYSE allows us to shift management and investor focus back on to our positive growth story’.Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.16 (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.16 (up from US$0.14 loss in 2Q 2023). Revenue: US$313.1m (down 15% from 2Q 2023). Net income: US$14.1m (up US$24.6m from 2Q 2023). Profit margin: 4.5% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2024 Results on Aug 07, 2024INNOVATE Corp. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • May 01INNOVATE Corp., Annual General Meeting, Jun 13, 2024INNOVATE Corp., Annual General Meeting, Jun 13, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect the four nominees identified in the accompanying proxy statement (the “Proxy Statement”), each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and to consider other matters.お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2024 Results on May 07, 2024INNOVATE Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Feb 28INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million.INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Feb 27INNOVATE Receives Written Notice from the New York Stock Exchange Regarding Non-Compliance with the Continued Listing Standard Set in Section 802.01C of the NYSE’s Listed Company ManualOn February 26, 2024, INNOVATE Corp. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) that it was not in compliance with the continued listing standard set in Section 802.01C of the NYSE’s Listed Company Manual (‘Section 802.01C’), as the average closing price of the Company’s common stock (the ‘Common Stock’) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. The Company plans to notify the NYSE that it intends to regain compliance and is considering all available options that are in the best interests of the Company and its shareholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock.お知らせ • Feb 13INNOVATE Corp. to Report Q4, 2023 Results on Mar 04, 2024INNOVATE Corp. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024New Risk • Dec 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$127m). Earnings have declined by 53% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€92.5m market cap, or US$99.8m).お知らせ • Oct 31INNOVATE Corp. to Report Q3, 2023 Results on Nov 09, 2023INNOVATE Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023お知らせ • Sep 22INNOVATE Corp. to Cease Suzi Herbst as Chief Operating Officer on or Around October 20, 2023On September 21, 2023, INNOVATE Corp. and Ms. Suzi Herbst, the Company’s Chief Operating Officer, determined by mutual agreement that Ms. Herbst’s employment with the Company would cease on or around October 20, 2023. Ms. Herbst’s resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、INNOVATE は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:PST0 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,337-56175206N/A12/31/20251,246-64120147N/A9/30/20251,100-756087N/A6/30/2025995-801739N/A3/31/20251,066-48120N/A12/31/20241,107-36-119N/A9/30/20241,232-261229N/A6/30/20241,365-186583N/A3/31/20241,420-405878N/A12/31/20231,423-38827N/A9/30/20231,471-351028N/A6/30/20231,519-34-48-28N/A3/31/20231,542-37-43-23N/A12/31/20221,637-41-30-9N/A9/30/20221,623-39-56-31N/A6/30/20221,595-45-40-15N/A3/31/20221,446-53-59-34N/A12/31/20211,205-80327N/A9/30/2021988-88-69-51N/A6/30/2021764-101-23-7N/A3/31/2021702-74-133N/A12/31/2020717-462341N/A9/30/2020260-6483106N/A6/30/2020517-46101125N/A3/31/2020815-3586112N/A12/31/20191,077-18N/A111N/A9/30/20191,881-1N/A287N/A6/30/20191,954143N/A416N/A3/31/20191,972176N/A375N/A12/31/20181,977139N/A341N/A9/30/20181,910145N/A106N/A6/30/20181,8151N/A-52N/A3/31/20181,697-67N/A-25N/A12/31/20171,634-50N/A7N/A9/30/20171,630-108N/A61N/A6/30/20171,636-109N/A50N/A3/31/20171,617-89N/A95N/A12/31/20161,558-105N/A79N/A9/30/20161,465-51N/A58N/A6/30/20161,329-52N/A66N/A3/31/20161,251-65N/A38N/A12/31/20151,121-40N/A-28N/A9/30/2015984-16N/A-17N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PST0の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PST0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PST0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PST0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PST0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PST0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 19:12終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋INNOVATE Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sarkis SherbetchyanB. Riley Securities, Inc.
Reported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.
お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2025 Results on Aug 05, 2025INNOVATE Corp. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 12, 2025INNOVATE Corp., Annual General Meeting, Jun 12, 2025.
お知らせ • Apr 17INNOVATE Corp. to Report Q1, 2025 Results on May 06, 2025INNOVATE Corp. announced that they will report Q1, 2025 results After-Market on May 06, 2025
お知らせ • Feb 28INNOVATE Corp. to Report Q4, 2024 Results on Mar 31, 2025INNOVATE Corp. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025
お知らせ • Jan 22INNOVATE Corp. Announces U.S. Food and Drug Administration Approved the MediBeacon TGFR for the Assessment of Kidney Function in Patients with Normal or Impaired Renal FunctionINNOVATE Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The approval of the TGFR by the FDA demonstrates proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis. The potential applications for the TGFR are numerous, and look forward to exploring them with clinicians both in the hospital and outpatient settings. The timing of FDA approval aligns well with the Fourth Quarter 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al in Kidney International with data that supports the utility of MediBeacon's patented agent Lumitrace. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within + - 30% of measured GFR (mGFR) values. For more information, including the FDA Summary of Safety and Effectiveness Data, refer to.
お知らせ • Oct 17INNOVATE Corp. to Report Q3, 2024 Results on Nov 06, 2024INNOVATE Corp. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
お知らせ • Sep 04INNOVATE Regains Compliance with NYSE Minimum Price RequirementINNOVATE Corp. (the ‘Company’) announced that it has received a letter from the New York Stock Exchange (‘NYSE’) dated August 27, 2024 (the ‘Compliance Notice’), notifying the Company that it is no longer considered below the NYSE’s continued listing criterion of a minimum average share price of USD 1.00 over a 30 trading-day period (the ‘NYSE Minimum Price Requirement’). ‘The Company’s team shared that we have received notification from the New York Stock Exchange regaining listing compliance,’ said Paul Voigt, the Company’s Chief Executive Officer. ‘Regaining compliance with NYSE allows us to shift management and investor focus back on to our positive growth story’.
Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.16 (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.16 (up from US$0.14 loss in 2Q 2023). Revenue: US$313.1m (down 15% from 2Q 2023). Net income: US$14.1m (up US$24.6m from 2Q 2023). Profit margin: 4.5% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2024 Results on Aug 07, 2024INNOVATE Corp. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • May 01INNOVATE Corp., Annual General Meeting, Jun 13, 2024INNOVATE Corp., Annual General Meeting, Jun 13, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect the four nominees identified in the accompanying proxy statement (the “Proxy Statement”), each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and to consider other matters.
お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2024 Results on May 07, 2024INNOVATE Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Feb 28INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million.INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Feb 27INNOVATE Receives Written Notice from the New York Stock Exchange Regarding Non-Compliance with the Continued Listing Standard Set in Section 802.01C of the NYSE’s Listed Company ManualOn February 26, 2024, INNOVATE Corp. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) that it was not in compliance with the continued listing standard set in Section 802.01C of the NYSE’s Listed Company Manual (‘Section 802.01C’), as the average closing price of the Company’s common stock (the ‘Common Stock’) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. The Company plans to notify the NYSE that it intends to regain compliance and is considering all available options that are in the best interests of the Company and its shareholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock.
お知らせ • Feb 13INNOVATE Corp. to Report Q4, 2023 Results on Mar 04, 2024INNOVATE Corp. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024
New Risk • Dec 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$127m). Earnings have declined by 53% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€92.5m market cap, or US$99.8m).
お知らせ • Oct 31INNOVATE Corp. to Report Q3, 2023 Results on Nov 09, 2023INNOVATE Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
お知らせ • Sep 22INNOVATE Corp. to Cease Suzi Herbst as Chief Operating Officer on or Around October 20, 2023On September 21, 2023, INNOVATE Corp. and Ms. Suzi Herbst, the Company’s Chief Operating Officer, determined by mutual agreement that Ms. Herbst’s employment with the Company would cease on or around October 20, 2023. Ms. Herbst’s resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices.